Nisan 2012
Nonsirotik portal hipertansiyonlu hastada dev peritoneal kist hidatik ve albendazole bagli aplastik anemi
Giant peritoneal cyst hydatid and albendazole-induced aplastic anemia in noncirrhotic portal hypertensive patient
- Ana Sayfa
- Sayılar
- Nisan 2012
- Nonsirotik portal hipertansiyonlu hastada dev peritoneal kist hidatik ve albendazole bagli aplastik anemi...
Department of 2Gastroenterology, Istanbul University, School of Medicine, Istanbul
Department of 3Gastroenterology, Düzce University, School of Medicine, Düzce
Özet
Albendazol genis spektrumlu antiparazitik bir ilaçtir. Yan etkilerinin minimal oldugu bildirilmistir. Hepatik, splenik ve peritoneal ekinokokkal kist nedeniyle albendazol baslanan, ikinci haftada febril nötropeni gelisen bir vaka sunulmustur. 49 yasinda erkek hasta karinda büyük kistik kitleleri nedeniyle müracaat etti. Hastanin hikayesinde nonsirotik portal hipertansiyon ve tekrarlayan kolanjit ataklari dikkat çekmekte idi. Albendazol sulfoksit peak dozu ve yarilanma ömrü karaciger hastaliklarinda ve baska ilaçlar kullanildiginda artmaktadir. Bu vakada ciddi nötropeni gelismis olmasinin altta yatan karaciger hastaligina bagli oldugu düsünülmüstür. Albendazol baslanacak bu tür hastalar kemik iligi toksisitesi yönünden sik kan sayimlari ile yakindan takip edilmeli, verilecek diger ilaçlara dikkat edilmelidir.
Abstract
Albendazole has broad-spectrum coverage as an antiparasitic drug, and the reported side effects have been minimal. We report the case of a patient with febrile neutropenia beginning during the second week of therapy for a hepatic, splenic and peritoneal echinococcal cyst. This case was a 49-year-old man who presented with a large cystic abdominal mass. His medical history was significant for non-cirrhotic portal hypertension and recurrent cholangitis. Albendazole sulfoxide peak dose and half-life are significantly prolonged by liver disease and concomitant administration of certain drugs. The severity and duration of albendazole-induced neutropenia in this case was likely related to the underlying liver disease. Frequent serial monitoring of blood counts and cessation of medication with any evidence of marrow toxicity in such patients are warranted.
